Clinical Trial Update: SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for SHR-1701 combined with famitinib in recurrent/metastatic nasopharyngeal carcinoma (Phase 1/Phase 2) with status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Famitinib (Famitinib)
• SHR-1701

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Nasopharyngeal Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN